Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 205, Issue 11, Pages 1739-1744Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jis261
Keywords
-
Categories
Funding
- Ministry of Foreign Affairs of The Netherlands [12454]
Ask authors/readers for more resources
Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53% were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available